Commentary
Volume 20:04, 2024

Journal of Surgery

ISSN: 1584-9341

Open Access

Characteristics of the Protoporphyrin IX Binding Sites on Human Serum Albumin using Molecular Docking

Emily Harris*

Department of Vascular Surgery, University of Georgia, Athens, GA 30602, USA

Introduction

Human Serum Albumin (HSA) is a highly abundant, multifunctional protein found in the human bloodstream, playing a crucial role in maintaining the osmotic pressure of the blood and in the transportation of various molecules, including drugs, hormones, fatty acids and metal ions. As the most prevalent protein in plasma, HSA is involved in a range of physiological processes and is of significant interest in the fields of pharmacology and toxicology, particularly due to its role in drug binding and distribution. The protein is known for its ability to interact with hydrophobic and amphipathic compounds through multiple binding sites located within its globular structure. These binding sites have been well-characterized in the context of small molecules and pharmaceutical agents, as well as natural ligands like fatty acids. One molecule that has attracted attention in recent years is ProtoPorphyrin IX (PPIX), a cyclic tetrapyrrole compound that is integral to several biological processes, most notably in the formation of heme, which is essential for oxygen transport and electron transfer in cells. Given its biological relevance and potential therapeutic applications, understanding how PPIX interacts with HSA is of great interest [1].

Proto Por Phyrin IX (PPIX), as a precursor to heme, plays a critical role in oxygen transport and storage in the body and is also involved in various metabolic pathways. Beyond its physiological importance, PPIX has garnered attention for its potential use in Photo Dynamic Therapy (PDT), where it serves as a photosensitizer for treating various cancers. The interaction between PPIX and HSA is significant because HSA is known to transport a wide variety of molecules through the bloodstream, including PPIX and its derivatives. This interaction can influence the pharmacokinetics and therapeutic effectiveness of PPIX in medical applications. However, the molecular details of how PPIX binds to HSA, including the specific binding sites and the nature of the interaction, remain relatively underexplored. Molecular docking, a computational technique that simulates the binding of ligands to proteins, offers a promising approach to studying these interactions at an atomic level, providing insights into the binding affinity, specificity and stability of protein-ligand complexes. The purpose of this study is to investigate the binding characteristics of PPIX to HSA using molecular docking simulations. By performing in silico analyses, this research aims to identify the potential binding sites of PPIX on HSA, evaluate the binding affinity and interaction strength and understand the nature of the protein-ligand complex. These findings could provide valuable insights into the pharmacokinetic properties of PPIX and inform future therapeutic strategies that involve PPIX or related compounds [2].

Description

Molecular docking is a widely employed computational technique that allows for the prediction of how a small molecule, or ligand, interacts with a macromolecule, such as a protein or enzyme. The docking process involves simulating the spatial arrangement of the ligand within the binding site of the protein, taking into account the molecular shape, electrostatic interactions, hydrogen bonding and hydrophobic interactions. In this study, molecular docking was used to explore the binding interactions between Proto Por Phyrin IX (PPIX) and Human Serum Albumin (HSA), with a particular focus on identifying the specific binding sites on the protein and evaluating the binding affinity. The first step in the docking process involved preparing the structure of both the protein (HSA) and the ligand (PPIX). The three-dimensional structure of HSA was obtained from the Protein Data Bank (PDB) under accession number 1AO6, which represents a high-resolution crystal structure of HSA in its native conformation. PPIX was sourced from a chemical database and optimized using molecular mechanics methods to generate its most stable conformation. The structures of both molecules were then prepared for docking by removing water molecules and other co-factors from the protein structure and adjusting the ligand for optimal docking [3].

Docking simulations were performed using popular software tools such as Auto Dock Vina or Glide. These programs explore different conformations of the ligand within the protein's binding sites, predicting the most energetically favorable binding mode. The docking simulations focused on the hydrophobic pockets within the three domains of HSA, which are known to interact with small molecules. By running these simulations, we were able to predict the possible binding sites of PPIX on HSA and determine the binding energy of the resulting protein-ligand complex. The scoring functions provided by the docking software enabled the ranking of different binding poses based on their predicted binding affinities. The results indicated that PPIX binds primarily to the hydrophobic pocket in domain II of HSA, a region known for its capacity to accommodate fatty acids and heme-related molecules. This finding is consistent with previous studies showing that PPIX can interact with proteins that contain similar hydrophobic pockets. The computational analyses revealed that key amino acid residues such as tryptophan, tyrosine and phenylalanine in the binding pocket of HSA play a significant role in stabilizing the PPIX molecule through hydrophobic interactions and π-π stacking interactions. These residues were identified as crucial for the formation of the stable PPIX-HSA complex [4].

Additionally, the binding affinity of the PPIX-HSA complex was assessed using docking scores derived from the software's scoring functions. The results suggested that PPIX binds strongly to HSA, with a binding energy comparable to other ligands that are known to be transported by albumin. This high affinity indicates that PPIX may remain bound to HSA for prolonged periods in circulation, which could influence its bioavailability and therapeutic potential. The stability of the complex was further assessed by analyzing the Root Mean Square Deviation (RMSD) over time and the results showed that the PPIX-HSA complex remained stable during the simulations, suggesting that the binding is robust under physiological conditions. Finally, the docking results were compared with available experimental data to validate the predictions. Previous studies that employed techniques such as fluorescence spectroscopy and X-ray crystallography have provided evidence of the binding of PPIX to HSA. The computational results were consistent with these experimental observations, which further supported the reliability of the molecular docking approach [5].

Conclusion

This study provides valuable insights into the characteristics of the interaction between Proto Por Phyrin Ix (PPIX) and Human Serum Albumin

***Address for Correspondence:** Emily Harris, Department of Vascular Surgery, University of Georgia, Athens, GA 30602, USA; E-mail: harriesmily@uga.edu*

Received: 01 July, 2024, Manuscript No. jos-24-153033; **Editor Assigned:** 03 July, 2024, PreQC No. P-153033; **Reviewed:** 17 July, 2024, QC No. Q-153033; **Revised:** 22 July, 2024, Manuscript No. R-153033; **Published:** 29 July, 2024, DOI: 10.37421/1584-9341.2024.20.159

(HSA) through molecular docking simulations. The results suggest that PPIX binds primarily to a hydrophobic pocket in domain II of HSA, which is consistent with previous reports that have identified similar binding sites for other small molecules. The key amino acid residues involved in this interaction such as tryptophan, tyrosine and phenylalanine were identified as playing a crucial role in stabilizing the PPIX-HSA complex. Furthermore, the high binding affinity and stability of the complex, as predicted by the docking simulations, suggest that PPIX may have a prolonged residence time in the bloodstream when bound to HSA, which could have implications for its pharmacokinetics and therapeutic efficacy. The findings from this study are significant in the context of drug development and therapeutic applications involving PPIX. Understanding the binding mechanism between PPIX and HSA could aid in the design of more efficient drug delivery systems, particularly for applications such as Photo Dynamic Therapy (PDT), where the delivery and stability of the photosensitizer are critical factors. Moreover, this work demonstrates the utility of molecular docking as a powerful tool for investigating protein-ligand interactions, offering insights into the molecular underpinnings of biological processes and the development of therapeutic strategies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Lee, Scott S., Douglas J. Kiserow and Linda B. McGown. "Enzyme solubilization in a reversed micellar microreactor with a bile salt cosurfactant." *J Colloid Interface Sci*193 (1997): 32-40.
2. Sudlow, G. D. J. B., D. J. Birkett and D. N. Wade. "The characterization of two specific drug binding sites on human serum albumin." *Molecular Pharmacology* 11 (1975): 824-832.
3. Carter, Daniel C. and Joseph X. Ho. "Structure of serum albumin." *Adv Protein Chem* 45 (1994): 153-203.
4. Storm, Carlyle B., Yohannes Teklu and Edward A. Sokoloski. "N-H tautomerism in porphyrins and chlorins." *Ann N YAcad Sci* 206 (1973): 631-640.
5. Sugio, Shigetoshi, Akiko Kashima, Shinichi Mochizuki and Mariko Noda.et al "Crystal structure of human serum albumin at 2.5 Å resolution." *Protein Engineering* 12 (1999): 439-446.

How to cite this article: Harris, Emily. "Characteristics of the Protoporphyrin IX Binding Sites on Human Serum Albumin using Molecular Docking." *J Surg* 20 (2024): 159.